Front. Oral. Health Frontiers in Oral Health Front. Oral. Health 2673-4842 Frontiers Media S.A. 10.3389/froh.2022.893486 Oral Health Retraction Retraction: Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings Frontiers Editorial Office * *Correspondence: Frontiers Editorial Office editorial.office@frontiersin.org

Approved by: Ricardo D. Coletta, Campinas State University, Brazil

This article was submitted to Oral Cancers, a section of the journal Frontiers in Oral Health

 22 03 2022 2022 3 893486 10 03 2022 10 03 2022 Copyright © 2022 Frontiers Editorial Office. 2022 Frontiers Editorial Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Retraction of the Original Research article Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings by Dobriyan, A., Gluck, I., Alon, E., Barshack, I., Yahalom, R., and Vered, M. (2021). Front. Oral. Health. 2:653104. doi: 10.3389/froh.2021.653104

The journal and Authors retract the 23 April 2021 article cited above for the following reason as provided by the Authors:

Following publication, the Authors were informed that they were not entitled to publish the raw data underlying the findings by the supplier of the analyzed drug.

Therefore, with the agreement of the Authors and the Chief Editor of the Oral Cancers specialty of Frontiers in Oral Health, the publication is being retracted.